Emergence of Biotech Mega-Rounds and Arruca Therapeutics

The chapter discusses the rise of biotech mega-rounds in early 2024, focusing on Arruca Therapeutics and their groundbreaking work in developing long-acting antibodies for autoimmune diseases like psoriasis. It delves into Arruca's unique origin story, innovative technology for antibody engineering, and their goal of optimizing dosing frequency while maintaining high disease clearance. The chapter also explores Arruca's Half Life Extension antibodies targeting IL-23 for psoriasis treatment, their decision to go public through a reverse merger, and the intricacies of assembling a pipe for the financing process.